Drug Name: Noscapine
Company: KineMed
Location: US-California
Drug Type: Small Molecule
Conditions: ALS, Parkinson’s disease, diabetic neuropathy
Mechanism Type: Microtubule dynamics modulator
Mechanism: Kinemed is developing noscapine and new analogues for neurodegenerative diseases and fibrotic diseases. Noscapine regulates abnormal microtubule (MT) dynamics, and reverses MT-mediated neuronal transport defects. The company has developed a proprietary technology for assessing MT turnover that is being developed as a biomarker in several neurodegenerative diseases, including ALS.
U.S. Status for ALS: Preclinical

[1] KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, Parkinson’s Disease, and Diabetic Neuropathy. BioSpace, 4 Sep 2014. Accessed 9 Mar 2016 from
[2] Kinemed. Neurodegenerative Diseases. Kinemed, n.d. Accessed 9 Mar 2016 from

Last updated March 9th, 2019

Share this: